secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2025-11-25T23:59:59+00:00
Accession:  0001104659-25-116049
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma receives Nasdaq delisting notices for failing MVLS and MVPHS rules
--------------------------------------------------------------------------------

- Notices dated Nov 19, 2025: MVLS below $50M and MVPHS below $15M for 30 consecutive business days.
- Company also fails alternative standard under Rule 5450(b)(3)(A) (total assets/revenue each <$50M).
- 180-day compliance period until May 18, 2026 to regain compliance; stock continues trading under LIMN.
- If not compliant by deadline, Nasdaq will issue delisting notice; Company may appeal or transfer to Capital Market.
- Management working to regain compliance but no assurance of success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/0001104659-25-116049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925116049/tm2532232d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-116049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer